Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods

• US 7,635,699 B2
• Filed: 12/21/2005
• Issued: 12/22/2009
• Est. Priority Date: 12/29/2004
• Status: Active Grant

• Current Assignee: Bristol-Myers Squibb Company
• Original Assignee: Bristol-Myers Squibb Company
• Inventors: Meng, Wei, Hamann, Lawrence G., Brigance, Robert
• Primary Examiner(s): Wilson; James O
• Assistant Examiner(s): Murray; Jeffrey H
• Application Number:
  US11/314,470
• Publication Number:
  US 20060178377A1
• Time in Patent Office: 1,462 Days
• Field of Search: None
• US Class Current: 514/259.1
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C07D 487/04 Ortho-condensed systems

Abstract

Compounds are provided having the formula (I)

wherein X for each occurrence is N or C-A, and R, Y, A and n are as defined herein, which compounds are dipeptidyl peptidase IV inhibitors and as such are useful in treating diabetes and micro- and macrovascular complications of diabetes, such as retinopathy, neuropathy, and nephropathy.

A method for treating diabetes and related diseases employing the above compounds is also provided.

Claims

1. A compound selected from the group consisting of:

2. A pharmaceutical composition comprising a compound as defined in claim 1 and a pharmaceutically acceptable carrier therefor.

3. A method for treating or delaying the progression or onset of Type II diabetes, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound as defined in claim 1.